The Medicines Company (NASDAQ:MDCO)

The Medicines Company, a global pharmaceutical company, provides various medicines to hospitals for advancing the treatment of critical care patients primarily in the United States and Europe. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; and Cleviprex, an intravenous small molecule calcium channel blocker for the reduction of blood pressure. The company’s developing products comprise Cangrelor, which is in Phase 3 clinical trial acts as an intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation; Oritavancin that is in Phase 3 clinical trial for the treatment of serious gram-positive bacterial infections, including acute bacterial skin and skin structure infections; and MDCO-2010, a small molecule serine inhibitor, is in Phase 2 clinical trial for the reduction of blood loss during surgery. It also provides MDCO-216 that is in Phase 1 clinical trial for the reversal of atherosclerotic plaque development and reduction of the risk of coronary events in patients with ACS; and Argatroban, which is a NDA filed direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis. The company sells its products through its sales representatives. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.